Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) FCF Margin (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of FCF Margin data on record, last reported at 18177.27% in Q4 2025.

  • For Q4 2025, FCF Margin rose 8426023.0% year-over-year to 18177.27%; the TTM value through Dec 2025 reached 390.81%, up 7670522.0%, while the annual FY2025 figure was 390.81%, 7670522.0% up from the prior year.
  • FCF Margin reached 18177.27% in Q4 2025 per VRDN's latest filing, down from 120.26% in the prior quarter.
  • Across five years, FCF Margin topped out at 120.26% in Q3 2025 and bottomed at 128804.17% in Q1 2025.
  • Average FCF Margin over 5 years is 42849.98%, with a median of 43348.21% recorded in 2023.
  • The widest YoY moves for FCF Margin: up 8426023bps in 2025, down -6599444bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 7717.76% in 2021, then plummeted by -329bps to 33138.1% in 2022, then plummeted by -63bps to 53990.28% in 2023, then tumbled by -90bps to 102437.5% in 2024, then surged by 82bps to 18177.27% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 18177.27% in Q4 2025, 120.26% in Q3 2025, and 100382.67% in Q2 2025.